> GlaxoSmithKline has submitted Solzira extended release tablets for restless leg syndrome, triggering a $23 million milestone payment to XenoPort. Report
> United Therapeutics says it is facing a likely FDA delay on the inhaled version of the hypertension drug Remodulin as it answers questions regarding the nebulizer that delivers the therapy. Release
> Shares of Australia's Avexa jumped on the news that its experimental HIV drug worked without presenting the adverse side effects seen in similar drugs. Researchers said that there was no signature resistance to ATC after 96 weeks of treatment in a Phase IIb trial, with over 85 percent of patients' HIV levels below detectable. Release
> Renovo has put the best spin it could on news that its drug Juvidex failed to meet its primary goal in a clinical trial late last week. The drug did not demonstrate an ability to close a wound, but researchers say the therapy did speed healing and improved the appearance of the skin grafts. Report
> Orexo has earned a $5 million milestone payment from Meda on the FDA's approval of Edluar, an insomnia therapy. Release
> The city of Chandler, AZ is considering establishing a biotech incubator. Story
> CytRx Corporation today touted positive data from an animal stroke trial indicating that treatment with its molecular chaperone amplifier drug candidate, arimoclomol, initiated at either six, 10, 24 or 48 hours post-stroke, demonstrated neurorestorative ability based on multiple behavioral tests measuring motor and sensory recovery. CytRx release
> It's good to be Jeff Kindler these days. The Pfizer CEO recently bagged the biggest pharma deal around, with his $68 million acquisition of Wyeth. The analysts who were agitating for him to make a big move are appeased, for now. And at a time when jobs are scarce and raises even more so, he got a 17 percent hike in 2008 pay. Report
> Five hundred Roche employees will be laid off as the Swiss pharmaceutical giant Roche prepares to close its Palo Alto research offices. Report
> Lawyers are keeping a close eye on the Seroquel case in Delaware Superior Court. With more than 15,000 plaintiffs claiming injury from the AstraZeneca drug, there's lots of money potentially at stake. Report
And Finally... Experimental research with insect larvae at Wageningen University and Simon Fraser University in Canada has shown that one virus particle is theoretically enough to cause infection and subsequent disease. Release